Literature DB >> 18728050

Incidence and risk factors of retinopathy of prematurity in a tertiary eye hospital in Tehran.

R Karkhaneh1, S Z Mousavi, M Riazi-Esfahani, S A Ebrahimzadeh, R Roohipoor, M Kadivar, L Ghalichi, S F Mohammadi, M R Mansouri.   

Abstract

AIM: To determine the incidence and risk factors of retinopathy of prematurity (ROP) in premature infants referred to a tertiary eye hospital during 2003-7 to provide preliminary evidence about ROP in Iran.
METHODS: In a cross-sectional study, data for premature infants screened for ROP in Farabi Eye Hospital including possible risk factors and eye exams' results were recorded and analysed using chi(2), univariate and multiple regressions. Severe ROP was defined as ROP needing treatment or stage 4 or 5 of ROP.
RESULTS: Among 953 premature infants, there were 329 (34.5%) different stages of ROP. Severe ROP was seen in 22.6% (215/953) of infants (16.5%: treatable, 6.1%: advanced untreatable). The mean gestational age (GA) and birth weight (BW) of infants with severe ROP were 28.8 (SD 2.4) weeks and 1256 (389) g respectively. Univariate analysis showed a significant relation between GA, BW, oxygen therapy, blood transfusion and ROP (p<0.001), while multiple-regression methods showed GA, BW and oxygen therapy as independent predictors of ROP (p<0.001, 0.019 and 0.033, respectively).
CONCLUSION: The authors observed a relatively high incidence of ROP in this series, especially its severe form affecting relatively more mature infants, which merits further investigation. GA, BW and oxygen therapy were independent ROP determinants.

Entities:  

Mesh:

Year:  2008        PMID: 18728050     DOI: 10.1136/bjo.2008.145136

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  22 in total

Review 1.  Transfusion related morbidity in premature babies: Possible mechanisms and implications for practice.

Authors:  Keith James Collard
Journal:  World J Clin Pediatr       Date:  2014-08-08

2.  Prevalence of retinopathy of prematurity in Iran: a systematic review and Meta-analysis.

Authors:  Saman Maroufizadeh; Amir Almasi-Hashiani; Reza Omani Samani; Mahdi Sepidarkish
Journal:  Int J Ophthalmol       Date:  2017-08-18       Impact factor: 1.779

Review 3.  Retinopathy of prematurity: a review of risk factors and their clinical significance.

Authors:  Sang Jin Kim; Alexander D Port; Ryan Swan; J Peter Campbell; R V Paul Chan; Michael F Chiang
Journal:  Surv Ophthalmol       Date:  2018-04-19       Impact factor: 6.048

Review 4.  Paediatric retinal detachment: a review.

Authors:  Raffaele Nuzzi; Carlo Lavia; Roberta Spinetta
Journal:  Int J Ophthalmol       Date:  2017-10-18       Impact factor: 1.779

5.  Screening for retinopathy of prematurity: a report from upper Egypt.

Authors:  Mahmoud M Nassar
Journal:  Int J Ophthalmol       Date:  2016-02-18       Impact factor: 1.779

6.  Distribution of retinopathy of prematurity and its risk factors.

Authors:  Amirkhosro Ghaseminejad; Pedram Niknafs
Journal:  Iran J Pediatr       Date:  2011-06       Impact factor: 0.364

7.  Incidence and Risk Factors of Retinopathy of Prematurity among Preterm Infants in Shiraz/Iran.

Authors:  Mojgan Bayat-Mokhtari; Narjes Pishva; Abbas Attarzadeh; Hamid Hosseini; Shahnaz Pourarian
Journal:  Iran J Pediatr       Date:  2010-09       Impact factor: 0.364

8.  Screening for retinopathy of prematurity in South of Iran.

Authors:  Mehrdad Afarid; Hamid Hosseini; Bagher Abtahi
Journal:  Middle East Afr J Ophthalmol       Date:  2012 Jul-Sep

9.  Surgical management in advanced stages of retinopathy of prematurity; our experience.

Authors:  Ramak Roohipoor; Reza Karkhaneh; Mohammad Riazi-Esfahani; Fariba Ghasemi; Mehdi Nili-Ahmadabadi
Journal:  J Ophthalmic Vis Res       Date:  2009-07

10.  New Predictors for Advanced Retinopathy of Prematurity among Neonates in Tehran/Iran.

Authors:  Karim Poorsattar Bejeh Mir; Parisa Mohagheghi; Arash Poorsattar Bejeh Mir; Seyed-Mohammad Fereshtehnejad
Journal:  Iran J Pediatr       Date:  2012-09       Impact factor: 0.364

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.